PROTEOMIC PROFILE CORRELATES TO MOLECULAR RESPONSE (MR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)

被引：0
|
作者：
Sgherza, N. [1 ,2 ]
Garrisi, V. M. [3 ]
Iacobazzi, A. [4 ]
Abbate, I. [3 ]
Cascavilla, N. [1 ,2 ]
Guarini, A. [4 ]
机构：
[1] Osped Casa Sollievo Sofferenza IRCCS, Ematol, San Giovanni Rotondo, Fg, Italy
[2] Osped Casa Sollievo Sofferenza IRCCS, Ctr Trapianto Cellule Staminali, San Giovanni Rotondo, Fg, Italy
[3] Ist Tumori Giovanni Paolo II, IRCCS, UOC Ematol, Bari, Italy
[4] Ist Tumori Giovanni Paolo II, IRCCS, Lab Patol Clin & Sperimentale, Bari, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P076
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [21] Chronic myeloid leukemia (CML) in 2012
    Michallet, M.
    ONCOLOGIE, 2012, 14 (10-11) : 559 - 560
  • [22] Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib
    Teitelbaum, A.
    Spencer, D.
    Bollu, V. K.
    Chastek, B.
    Coombs, J.
    Kulakodlu, M.
    Morlock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib
    Yang, Allen S.
    Jillella, Anand
    Miller, Carole B.
    Akard, Luke P.
    DeAngelo, Daniel J.
    Goldberg, Stuart L.
    Williams, Denise
    Radich, Jerald P.
    BLOOD, 2009, 114 (22) : 868 - 869
  • [24] EARLY MOLECULAR RESPONSE TO NILOTINIB IN PATIENTS WHO FAILED IMATINIB IS ASSOCIATED WITH A HIGHER PROBABILITY OF CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML)
    Hughes, T.
    Kim, D.
    Martinelli, G.
    Branford, S.
    Mueller, M.
    Beppu, L.
    Goh, H.
    Soverini, S.
    Shou, Y.
    Reynolds, J.
    Woodman, R.
    Kantarjian, H.
    Saglio, G.
    Radich, J.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 54 - 54
  • [25] Better molecular response (MR) to imatinib (IM) in early chronic phase (CP) versus late CP chronic myeloid leukemia (CML) patients (pts) in complete cytogenetic response (CCR): A comparison at 24 months of 2 clinical trials of the GIMEMA working party on CML on behalf of the GIMEMA working party on chronic myeloid leukemia (GIMEMA-CML).
    Poerio, A
    Amabile, M
    Iacobucci, I
    Soverini, S
    Colarossi, S
    Ottaviani, E
    Terragna, C
    Grafone, T
    Luatti, S
    Castagnetti, F
    Pane, F
    Saglio, G
    Russo, D
    Rosti, G
    Baccarani, M
    Martinelli, G
    BLOOD, 2005, 106 (11) : 319A - 319A
  • [26] PHILADELPHIA (PH) NEGATIVE CHRONIC MYELOID-LEUKEMIA (CML) - MOLECULAR UPDATE OF 14 PATIENTS
    GABERT, J
    COSTELLO, R
    TOIRON, Y
    LAFAGEPOCHITALOFF, M
    BRUNEL, V
    BOUABDALLAH, R
    GASTAUT, JA
    MARANINCHI, D
    SAINTY, D
    BLOOD, 1994, 84 (10) : A605 - A605
  • [27] Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).
    Goldberg, Stuart L.
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Hehlmann, Ruediger
    Khoury, Hanna Jean
    Mauro, Michael J.
    Michallet, Mauricette
    Paquette, Ronald
    Simonsson, Bengt
    Foreman, Aimee
    Mohamed, Hesham
    Subar, Milayna
    Zyczynski, Teresa Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Investigations on molecular determinants of durable molecular response in chronic myeloid leukemia patients
    Iqbal, Zafar
    ADVANCEMENTS IN LIFE SCIENCES, 2022, 9 (01): : 67 - 74
  • [29] THERAPEUTIC RESPONSE OF BLASTIC CRISIS OF CHRONIC MYELOID-LEUKEMIA (CML)
    CASIROLA, G
    IPPOLITI, G
    INVERNIZZI, R
    MARINI, G
    ACTA HAEMATOLOGICA, 1978, 59 (05) : 317 - 318
  • [30] HYPOPHOSPHATEMIA AS A PREDICTOR OF RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH IMATINIB
    Garrido, T.
    Amorim, M.
    Gomes, P.
    Trigo, F.
    Guimaraes, J.
    HAEMATOLOGICA, 2014, 99 : 339 - 339
12345